Best Practices and Barriers to Engaging People with Substance Use Disorders in Treatment. REFERENCES


  1. Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality. Key Substance Use and Mental Health Indicators in the United States: Results from the 2015 National Survey on Drug Use and Health. Publication No. SMA 16-4984, NSDUH Series H-51. Rockville, MD: SAMHSA; 2016.

  2. Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality. 2015 National Survey on Drug Use and Health: Detailed Tables Prevalence Estimates, Standard Errors, P Values, and Sample Sizes. Rockville, MD: SAMHSA; 2016.

  3. Centers for Disease Control and Prevention (CDC). Prescription Opioid Overdose Data. CDC website. Atlanta, GA: CDC. Updated August 1, 2017. Accessed September 21, 2017.

  4. Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. Publication No. SMA 15-4927, NSDUH Series H-50. Rockville, MD: SAMHSA; 2015.

  5. Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies. Treatment Episode Data Set (TEDS), 2006: Discharges from Substance Abuse Treatment Services. DASIS Series: S-46, HHS Publication No. (SMA) 09-4378. Rockville, MD: SAMHSA; 2009.

  6. Analysis of Medicaid HEDIS data by the National Committee for Quality Assurance, as presented in the CMS Medicaid Innovation Accelerator Program Substance Use Disorder (SUD) Targeted Learning Opportunities Webinar 15 on State of SUD-Related Quality Metrics. July 11, 2016. Accessed September 21, 2017.

  7. Acevedo A, Garnick DW, Lee MT, et al. Racial and ethnic differences in substance abuse treatment initiation and engagement. J Ethn Subst Abuse. 2012; 11(1): 1-21. doi:10.1080/15332640.2012.652516.

  8. Fingerhood MI, King VL, Brooner RK, Rastegar DA. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment. Subst Abus. 2014; 35(2): 22-126. doi:10.1080/08897077.2013.819828.

  9. Ilgen MA, Price AM, Burnett-Zeigler I, et al. Longitudinal predictors of addictions treatment utilization in treatment-naïve adults with alcohol use disorders. Drug Alcohol Depend. 2011; 113(2-3): 215-221. doi:10.1016/j.drugalcdep.2010.08.006.

  10. Resko SM, Mendoza NS. Early attrition from treatment among women with co-occurring substance use disorders and PTSD. J Soc Work Pract Addict. 2012; 12(4): 348-369. doi:10.1080/1533256X.2012.728104.

  11. Brown CH, Bennett ME, Li L, Bellack AS. Predictors of initiation and engagement in substance abuse treatment among individuals with co-occurring serious mental illness and substance use disorders. Addict Behav. 2011; 36(5): 439-447. doi:10.1016/j.addbeh.2010.12.001.

  12. U.S. Department of Health and Human Services (HHS), Office of the Surgeon General. Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health. HHS Publication No. (SMA) 16-4991. Washington, DC: Office of the Surgeon General; 2016.

  13. Miller NS, Sheppard LM, Colenda CC, Magen J. Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Acad Med. 2001; 76(5): 410-418. doi:10.1097/00001888-200105000-00007.

  14. Saitz R, Sullivan L, Samet J. Training community-based clinicians in screening and brief intervention for substance abuse problems: Translating evidence into practice. Subst Abus. 2000; 21(1): 21-31. doi:10.1023/A:1007755817351.

  15. Polydorou S, Gunderson EW, Levin FR. Training physicians to treat substance use disorders. Curr Psychiatry Rep. 2008; 10(5): 399-404. doi:10.1007/s11920-008-0064-8.

  16. van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. Drug Alcohol Depend. 2013; 131(1-2): 23-35. doi:10.1016/j.drugalcdep.2013.02.018.

  17. Knudsen HK, Roman PM, Oser CB. Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. J Addict Med. 2010; 4(2): 99-107. doi:10.1097/ADM.0b013e3181b41a32.

  18. Arfken CL, Johanson C-E, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. J Subst Abuse Treat. 2010; 39(2): 96-104. doi:10.1016/j.jsat.2010.05.004.

  19. Dick AW, Pacula RL, Gordon AJ, et al. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11. Health Aff(Millwood). 2015; 34(6): 1028-1034. doi:10.1377/hlthaff.2014.1205.

  20. Centers for Medicare & Medicaid Services (CMS). Medicaid Drug Utilization Review. State Comparison/Summary Report FFY 2015. Annual Report. Baltimore, MD: CMS; 2016. Accessed September 21, 2017.

  21. Weber EW. Failure of physicians to prescribe pharmacotherapies for addiction: Regulatory restrictions and physician resistance. J Heal Care L Pol'y. 2010; 13(1): 49-76.

  22. National Center on Addiction and Substance Abuse (CASA). Uncovering Coverage Gaps: A Review of Addiction Benefits in ACA Plans. New York, NY: CASA; 2016.

  23. Quinn A, Reif S, Merrick EL, Horgan CM, Garnick DW, Stewart MT. How do private health plans manage specialty behavioral health treatment entry and continuing care? Psychiatr Serv. 2017 May 15. [Epub ahead of print]. doi: 10.1176/

  24. Grogan CM, Andrews C, Abraham A, Humphreys K, Pollack HA, Smith BT, Friedmann PD. Survey highlights differences In Medicaid coverage for substance use treatment and opioid use disorder medications. Health Aff (Millwood). 2016;35(12):2289-2296. doi: 10.1377/hlthaff.2016.0623.

  25. Substance Abuse and Mental Health Services Administration (SAMHSA). Medicaid Coverage and Financing of Medications to Treat Alcohol and Opioid Use Disorders. HHS Publication No. SMA-14-4854. Rockville, MD: SAMHSA; 2014.

  26. Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric disorders. Soc Work Public Health. 2013; 28(3-4): 388-406. doi:10.1080/19371918.2013.774673.

  27. Schaefer JA, Cronkite RC, Hu KU. Differential relationships between continuity of care practices, engagement in continuing care, and abstinence among subgroups of patients with substance use and psychiatric disorders. J Stud Alcohol Drugs. 2011; 72(4): 611-621. doi:10.15288/jsad.2011.72.611.

  28. McLellan AT, Chalk M, Bartlett J. Outcomes, performance, and quality: What's the difference? J Subst Abuse Treat. 2007; 32(4): 331-340. doi:10.1016/j.jsat.2006.09.004.

  29. National Committee for Quality Assurance (NCQA). The State of Health Care Quality 2013: Improving Quality and Patient Experience. 2013. Washington, DC: NCQA; 2013. Accessed September 21, 2017.

  30. Han B, Gfroerer JC, Colliver JD, Penne MA. Substance use disorder among older adults in the United States in 2020. Addiction. 2009; 104(1): 88-96. doi:10.1111/j.1360-0443.2008.02411.x.

  31. Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015; 72(8): 757-766. doi:10.1001/jamapsychiatry.2015.0584.

  32. FAIR Health. The Impact of the Opioid Crisis on the Healthcare System: A Study of Privately Billed Services. New York, NY: FAIR Health; 2016.

  33. Substance Abuse and Mental Health Services Administration (SAMHSA). Center for Behavioral Health Statistics and Quality. Results from the 2013 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: SAMHSA; 2013.

  34. Jones CM, Logan J, Gladden R, Bohm MK. Vital Signs: Demographic and substance use trends among heroin users--United States, 2002-2013. Morb Mortal Wkly Rep. 2015; 64(26): 719-725.

  35. Gryczynski J, Schwartz RP, O'Grady KE, Restivo L, Mitchell SG, Jaffe JH. Understanding patterns of high-cost health care use across different substance user groups. Health Aff (Millwood). 2016; 35(1): 12-19. doi:10.1377/hlthaff.2015.0618.

  36. Centers for Disease Control and Prevention (CDC). Heroin Overdose Data. CDC website. Atlanta, GA: CDC. Updated January 26, 2017. Accessed September 21, 2017.

  37. Centers for Disease Control and Prevention (CDC). Increases in Heroin Overdose Deaths --28 States, 2010 to 2012. Morb Mortalitiy Wkly Rep. 2014; 63(39): 849-854.

  38. Rudd R, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths --United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016; 65(50-51): 1445-1452.

  39. Bondurant SR, Lindo JM, Swenson ID. National Bureau of Economic Research (NBER) Working Paper No. 22610. Substance Abuse Treatment Centers and Local Crime. Cambridge, MA: NBER; 2016.

  40. Wen H, Hockenberry JM, Cummings JR. National Bureau of Economic Research (NBER) Working Paper No. 20537. The Effect of Substance Use Disorder Treatment Use on Crime: Evidence from Public Insurance Expansions and Health Insurance Parity Mandates. Cambridge, MA: NBER; 2014.

  41. Centers for Disease Control and Prevention (CDC). Alcohol and Public Health: Alcohol-Related Disease Impact (ARDI). Average for United States 2006-2010 Alcohol-Attributable Deaths Due to Excessive Alcohol Use. CDC website. Atlanta, GA: CDC; 2013. Accessed September 21, 2017.

  42. Bouchery EE, Harwood HJ, Sacks JJ, Simon CJ, Brewer RD. Economic costs of excessive alcohol consumption in the US, 2006. Am J Prev Med. 2011; 41(5): 516-524.

  43. Heilig M, Goldman D, Berrettini W, O'Brien CP. Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci. 2011; 12(11): 670-684. doi:10.1038/nrn3110.

  44. McKay JR, Krandler HR, Kampman KM, Ashare RL, Schnoll RA. Psychopharmacological treatments for substance use disorders. In: Nathan N, JM G, eds. A Guide to Treatments That Work. 3rd ed. New York, NY: Oxford University Press; 2015: 763-800.

  45. Lopez-Quintero C, Roth KB, Eaton WW, et al. Mortality among heroin users and users of other internationally regulated drugs: A 27-year follow-up of users in the Epidemiologic Catchment Area Program household samples. Drug Alcohol Depend. 2016; 156: 104-111. doi:10.1016/j.drugalcdep.2015.08.030.

  46. PEW Charitable Trusts. The Case for Medication-Assisted Treatment. Washington, DC: The Pew Charitable Trusts; 2017. Accessed September 21, 2017.

  47. Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016; 54(10): 901-906. doi:10.1097/MLR.0000000000000625.

  48. Potter JS, Dreifuss JA, Marino EN, et al. The multi-site prescription opioid addiction treatment study: 18-month outcomes. J Subst Abuse Treat. 2015; 48(1): 62-69. doi:10.1016/j.jsat.2014.07.009.

  49. Potter JS, Marino EN, Hillhouse MP, et al. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: Findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs. 2013; 74(4): 605-613.

  50. Nielsen S, Hillhouse M, Thomas C, Hasson A, Ling W. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med. 2013; 7(1): 33-38. doi:10.1097/ADM.0b013e318277e92e.

  51. Hasin DS, Grant BF. The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings. Soc Psychiatry Psychiatr Epidemiol. 2015; 50(11): 1609-1640. doi:10.1007/s00127-015-1088-0.

  52. Dreifuss JA, Griffin ML, Frost K, et al. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug Alcohol Depend. 2013; 131(1-2): 112-118. doi:10.1016/j.drugalcdep.2012.12.010.

  53. Mancino M, Curran G, Han X, Allee E, Humphreys K, Booth BM. Predictors of attrition from a national sample of methadone maintenance patients. Am J Drug Alcohol Abuse. 2010; 36(3): 155-160. doi:10.3109/00952991003736389.

  54. Gryczynski J, Schwartz RP, Salkever DS, Mitchell SG, Jaffe JH. Patterns in admission delays to outpatient methadone treatment in the United States. J Subst Abuse Treat. 2011; 41(4): 431-439. doi:10.1016/j.jsat.2011.06.005.

  55. Saloner B, Lê Cook B. Blacks and Hispanics are less likely than whites to complete addiction treatment, largely due to socioeconomic factors. Health Aff(Millwood). 2013; 32(1): 135-145. doi:10.1377/hlthaff.2011.0983.

  56. Cook B, Alegría M. Racial-ethnic disparities in substance abuse treatment: The role of criminal history and socioeconomic status. Psychiatr Serv. 2011; 62(11): 1273-1281. doi:10.1176/ps.62.11.pss6211_1273.

  57. Parran TV, Adelman CA, Merkin B, et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010; 106(1): 56-60. doi:10.1016/j.drugalcdep.2009.07.013.

  58. Griffin ML, Dodd DR, Potter JS, et al. Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder. Am J Drug Acohol Abus. 2013; 40(2): 157-162. doi:10.3109/00952990.2013.842241.

  59. Copersino ML, Schretlen DJ, Fitzmaurice G, et al. Effects of cognitive impairment on substance abuse treatment attendance: Predictive validation of a brief cognitive screening measure. Am J Drug Alcohol Abuse. 2012; 38(3): 246-250. doi:10.3109/00952990.2012.670866.

  60. Hibbard JH, Greene J. What the evidence shows about patient activation: Better health outcomes and care experiences; fewer data on costs. Health Aff (Millwood). 2013; 32(2): 207-214. doi:10.1377/hlthaff.2012.1061.

  61. James J. Health Policy Brief: Patient engagement. Health Aff. 2013; 36(1). Accessed September 21, 2017.

  62. Greene J, Hibbard JH. Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med. 2012; 27(5): 520-526. doi:10.1007/s11606-011-1931-2.

  63. Shortell SM, Sehgal NJ, Bibi S, et al. An early assessment of accountable care organizations' efforts to engage patients and their families. Med Care Res Rev. 2015; 72(5): 580-604. doi:10.1177/1077558715588874.

  64. Mark TL, Lubran R, McCance-Katz EF, Chalk M, Richardson J. Medicaid coverage of medications to treat alcohol and opioid dependence. J Subst Abuse Treat. 2015; 55: 1-5. doi:10.1016/j.jsat.2015.04.009.

  65. Substance Abuse and Mental Health Services Administration (SAMHSA). 42 CFR §§ 8.1 et seq. Medication Assisted Treatment for Opioid Use Disorders.

  66. Lee MT, Garnick DW, O'Brien PL, et al. Adolescent treatment initiation and engagement in an evidence-based practice initiative. J Subst Abuse Treat. 2012; 42(4): 346-355. doi:10.1016/j.jsat.2011.09.005.

  67. Hoffman KA, Ford JH, Tillotson CJ, Choi D, McCarty D. Days to treatment and early retention among patients in treatment for alcohol and drug disorders. Addict Behav. 2011; 36(6): 643-647. doi:10.1016/j.addbeh.2011.01.031.

  68. Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2002-2012. National Admissions to Substance Abuse Treatment Services, BHSIS Series S-71, HHS Publication No. (SMA) 14-4850. Rockville, MD: SAMHSA; 2014.

  69. Carroll KM. Dissemination of evidence-based practices: How far we've come, and how much further we've got to go. Addiction. 2012; 107(6): 1031-1033. doi:10.1111/j.1360-0443.2011.03755.x.

  70. Fullerton CA, Kim M, Thomas CP, et al. Medication-assisted treatment with methadone: Assessing the evidence. Psychiatr Serv. 2014; 65(2): 146-157. doi:10.1176/

  71. Thomas CP, Fullerton CA, Kim M, et al. Medication-assisted treatment with buprenorphine: Assessing the evidence. Psychiatr Serv. 2014; 65(2): 158-170. doi:10.1176/

  72. McHugh RK, Hearon BA, Otto MW. Cognitive behavioral therapy for substance use disorders. Psychiatr Clin North Am. 2010; 33(3). doi:10.1016/j.psc.2010.04.012.

  73. Milward J, Lynskey M, Strang J. Solving the problem of non-attendance in substance abuse services. Drug Alcohol Rev. 2014; 33(6): 625-636. doi:10.1111/dar.12194.

  74. Petry NM, Weinstock J, Alessi SM. A randomized trial of contingency management delivered in the context of group counseling. J Consult Clin Psychol. 2011; 79(5): 686-696. doi:10.1037/a0024813.

  75. Kidorf , Brooner RK, Gandotra N, et al. Reinforcing integrated psychiatric service attendance in an opioid-agonist program: A randomized and controlled trial. Drug Alcohol Depend. 2013; 133(1): 30-36. doi:10.1016/j.drugalcdep.2013.06.005.

  76. Elwyn G, Dehlendorf C, Epstein RM, Marrin K, White J, Frosch DL. Shared decision making and motivational interviewing: Achieving patient-centered care across the spectrum of health care problems. Ann Fam Med. 2014; 12(3): 270-275. doi:10.1370/afm.1615.

  77. Rollnick S, Butler CC, Kinnersley P, Gregory J, Mash B. Motivational interviewing. BMJ. 2010; 340(513): c1900. doi:10.1136/bmj.c1900.

  78. Morgenstern J, Kuerbis A, Amrhein P, Hail L, Lynch K, McKay JR. Motivational interviewing: A pilot test of active ingredients and mechanisms of change. Psychol Addict Behav. 2012; 26(4): 859-869. doi:10.1037/a0029674.

  79. Kidorf M, King VL, Gandotra N, Kolodner K, Brooner RK. Improving treatment enrollment and re-enrollment rates of syringe exchangers: 12-month outcomes. Drug Alcohol Depend. 2012; 124(1-2): 162-166. doi:10.1016/j.drugalcdep.2011.12.008.

  80. Garner BR, Godley SH, Dennis ML, Hunter BD, Bair CML, Godley MD. Using pay for performance to improve treatment implementation for adolescent substance use disorders: Results from a cluster randomized trial. Arch Pediatr Adolesc Med. 2012; 166(10): 938-944. doi:10.1001/archpediatrics.2012.802.

  81. Haley SJ, Dugosh KL, Lynch KG. Performance contracting to engage detoxification-only patients into continued rehabilitation. J Subst Abuse Treat. 2017; 40(2): 123-131. doi:10.1016/j.jsat.2010.09.001.

  82. McLellan AT, Kemp J, Brooks A, Carise D. Improving public addiction treatment through performance contracting: The Delaware experiment. Health Policy. 2017; 87(3): 296-308. doi:10.1016/j.healthpol.2008.01.010.

  83. Stewart MT, Horgan CM, Garnick DW, Ritter G, McLellan AT. Performance contracting and quality improvement in outpatient treatment: Effects on waiting time and length of stay. J Subst Abuse Treat. 2017; 44(1): 27-33. doi:10.1016/j.jsat.2012.02.001.

  84. Fullerton CA, Henke RM, Crable EL, Hohlbauch A, Cummings N. The impact of medicare acos on improving integration and coordination of physical and behavioral health care. Health Aff (Millwood). 2016; 35(7): 1257-1265. doi:10.1377/hlthaff.2016.0019.

  85. Huskamp H, Barry C. Substance use disorder treatment under new payment and delivery system models. Paper presented June 24, 2014, at the 5th Biennial Conference of the American Society of Health Economists. Accessed September 21, 2017.

  86. Hibbard JH, Greene J, Sacks R, Overton V. Does compensating primary care providers to produce higher quality make them more or less patient centric? Med Care Res Rev. 2015; 72(4): 481-495. doi:10.1177/1077558715586291.

  87. Abraham AJ, Andrews CM, Yingling ME, Shannon J. Geographic disparities in availability of opioid use disorder treatment for Medicaid enrollees. Health Serv Res. 2017 Mar 27. [Epub ahead of print]. doi: 10.1111/1475-6773.12686.

  88. Cummings JR, Wen H, Ko M. Decline in public substance use disorder treatment centers most serious in counties with high shares of black residents. Health Aff(Millwood). 2016; 35(6): 1036-1044. doi:10.1377/hlthaff.2015.1630.

  89. Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015; 13(1): 23-26. doi:10.1370/afm.1735.

  90. Levit KR, Mark TL, Coffey RM, et al. Federal spending on behavioral health accelerated during recession as individuals lost employer insurance. Health Aff(Millwood). 2013; 32(5): 952-962. doi:10.1377/hlthaff.2012.1065.

  91. Levit KR, Stranges E, Coffey RM, et al. Current and future funding sources for specialty mental health and substance abuse treatment providers. Psychiatr Serv. 2013; 64(6): 512-519. doi:10.1176/

  92. Burns RM, Pacula RL, Bauhoff S, et al. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013. Subst Abus. 2015; 37(1): 63-69. doi:10.1080/08897077.2015.1080208.

  93. Capoccia VA, Grazier KL, Toal C, Ford JH, Gustafson DH. Massachusetts's experience suggests coverage alone is insufficient to increase addiction disorders treatment. Health Aff (Millwood). 2012; 31(5): 1000-1008. doi:10.1377/hlthaff.2011.0326.

  94. Tai B, Volkow ND. Treatment for substance use disorder: Opportunities and challenges under the affordable care act. Soc Work Public Health. 2013; 28(3-4): 165-174. doi:10.1080/19371918.2013.758975.

  95. Cummings JR, Wen H, Ko M, Druss BG. Race/Ethnicity and geographic access to Medicaid substance use disorder treatment facilities in the United States. JAMA Psychiatry. 2014; 71(2): 190-196. doi:10.1001/jamapsychiatry.2013.3575.

  96. Saloner B, Lê Cook B. An ACA provision increased treatment for young adults with possible mental illnesses relative to comparison group. Health Aff(Millwood). 2014; 33(8): 1425-1434. doi:10.1377/hlthaff.2014.0214.

  97. Busch SH, Epstein AJ, Harhay MO, et al. The effects of federal parity on substance use disorder treatment. Am J Manag Care. 2014; 20(1): 76-82.

  98. Centers for Medicare & Medicaid Services (CMS). Medicaid and Children's Health Insurance Programs; Mental Health Parity and Addiction Equity Act of 2008; the Application of Mental Health Parity Requirements to Coverage Offered by Medicaid Managed Care Organizations, the Children's Health Insurance Program (CHIP), and Alternative Benefit Plans. 81 FR 18389. 42 CFR 438, 440, 456, 457. March 30, 2016. Accessed September 21, 2017.

  99. National Committee for Quality Assurance (NCQA). Technical Specifications for Health Plans. Washington, DC: NCQA; 2015.

  100. National Quality Forum (NQF). About Us. NQF website; 2017. Accessed September 21, 2017.

  101. Garnick DW, Lee MT, Horgan C, et al. Lessons from five states: Public sector use of the Washington Circle performance measures. J Subst Abuse Treat. 2011; 40(3): 241-254. doi:10.1016/j.jsat.2010.11.008.

  102. Garnick DW, Horgan CM, Chalk M. Performance measures for alcohol and other drug services. Alcohol Res Health. 2006; 29(1): 19-26.

  103. National Committee for Quality Assurance (NCQA). HEDIS® and Performance Measurement: Measuring Performance. NCQA website; 2017. Accessed September 21, 2017.

  104. National Quality Forum (NQF). Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET). NQF Web site; 2017. Accessed September 21, 2017.

  105. Centers for Medicare & Medicaid Services (CMS). 2017 Core Set of Adult Health Care Quality Measures for Medicaid (Adult Core Set). CMS website; 2017. Accessed September 21, 2017.

  106. Personal communications from D.E.B. Potter, Staff Co-Chair, U.S. Department of Health and Human Services, Behavioral Health Coordinating Committee, Subcommittee on Quality Measures.

  107. Substance Abuse and Mental Health Services Administration (SAMHSA). Quality Measures. SAMHSA website. Last updated April 18, 2017. Accessed September 21, 2017.

  108. Centers for Medicare & Medicaid Services (CMS). MIPS Overview. Quality Payment Program website; 2017. Accessed September 21, 2017.

  109. Zainulbhai S, Goldberg L, Ng W, Montgomery A. Assessing care integration for dual-eligible beneficiaries: A review of quality measures chosen by states in the financial alignment initiative. Issue Brief (Commonw Fund). 2014; 2: 1-20.

  110. National Quality Forum (NQF). Alignment Tool. Measure Applications Partnership (MAP) Duals Eligible Beneficiaries Workgroup. NQF website. 2015. Accessed September 21, 2017.

  111. Center for Health Care Strategies. Quality Measurement Approaches of State Medicaid Accountable Care Organization Programs, Technical Assistance Tool. Trenton, NJ: Center for Health Care Strategies; 2017. Accessed September 21, 2017.

  112. Harris AHS, Reeder RN, Ellerbe LS, Bowe TR. Validation of the treatment identification strategy of the HEDIS addiction quality measures: Concordance with medical record review. BMC Health Serv Res. 2011; 11(1): 73. doi:10.1186/1472-6963-11-73.

  113. Harris AHS, Ellerbe L, Phelps TE, et al. Examining the specification validity of the HEDIS quality measures for substance use disorders. J Subst Abuse Treat. 2015; 53: 16-21. doi:10.1016/j.jsat.2015.01.002.

  114. Harris AHS, Humphreys K, Bowe T, Tiet Q, Finney JW. Does meeting the HEDIS substance abuse treatment engagement criterion predict patient outcomes? J Behav Heal Serv Res. 2010; 37(1): 25-39. doi:10.1007/s11414-008-9142-2.

  115. Garnick DW, Lee MT, O'Brien PL, et al. The Washington circle engagement performance measures' association with adolescent treatment outcomes. Drug Alcohol Depend. 2012; 124(3): 250-258. doi:10.1016/j.drugalcdep.2012.01.011.

  116. Garnick DW, Horgan CM, Acevedo A, et al. Criminal justice outcomes after engagement in outpatient substance abuse treatment. J Subst Abuse Treat. 2014; 46(3): 295-305. doi:10.1016/j.jsat.2013.10.005.

  117. Dunigan R, Acevedo A, Campbell K, et al. Engagement in outpatient substance abuse treatment and employment outcomes. J Behav Heal Serv Res. 2014; 41(1): 20-36. doi:10.1007/s11414-013-9334-2.

  118. National Committee for Quality Assurance (NCQA). Summary Table of Measures, Product Lines and Changes. HEDIS 2018, Volume 2; 2017. 2018 Measures.pdf?ver=2017-06-28-134644-370. Accessed September 21, 2017.

  119. National Committee for Quality Assurance (NCQA). Quality Compass. NCQA website. 2015. Accessed September 21, 2017.

  120. Glasner-Edwards S, Rawson R. Evidence-based practices in addiction treatment: review and recommendations for public policy.Health Policy. 2010; 97(2-3): 93-104. doi:10.1016/j.healthpol.2010.05.013.

  121. Labbe AK, Slaymaker V, Kelly JF. Toward enhancing 12-step facilitation among young people: a systematic qualitative investigation of young adults' 12-step experiences. Subst Abus. 2014; 35(4): 399-407. doi:10.1080/08897077.2014.950001.

  122. Kelly JF, Stout RL, Slaymaker V. Emerging adults' treatment outcomes in relation to 12-step mutual-help attendance and active involvement. Drug Alcohol Depend. 2013; 129(1-2): 151-157. doi:10.1016/j.drugalcdep.2012.10.005.

  123. Labbe AK, Greene C, Bergman BG, Hoeppner B, Kelly JF. The importance of age composition of 12-step meetings as a moderating factor in the relation between young adults' 12-step participation and abstinence. Drug Alcohol Depend. 2013; 133(2): 541-547. doi:10.1016/j.drugalcdep.2013.07.021.

  124. O'Malley SS, Corbin WR, Leeman RF, et al. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. J Clin Psychiatry. 2015; 76(2): e207-e213. doi:10.4088/JCP.13m08934.

  125. Croff RL, Rieckmann TR, Spence JD. Provider and state perspectives on implementing cultural-based models of care for american Indian and alaska native patients with substance use disorders. J Behav Health Serv Res. 2014; 41(1): 64-79. doi:10.1007/s11414-013-9322-6.

  126. Gaudiano BA, Weinstock LM, Miller IW. Improving treatment adherence in bipolar disorder: A review of current psychosocial treatment efficacy and recommendations for future treatment development. Behav Modif. 2008; 32(3): 267-301. doi:10.1177/0145445507309023.

  127. Molfenter T. Reducing appointment no-shows: Going from theory to practice. Subst Use Misuse. 2013; 48(9): 743-749. doi:10.3109/10826084.2013.787098.

  128. Loveland D, Driscoll H. Examining attrition rates at one specialty addiction treatment provider in the United States: A case study using a retrospective chart review. Subst Abuse Treat Prev Policy. 2014; 9(41). doi:10.1186/1747-597X-9-41.

  129. Rutkowski BA, Gallon S, Rawson RA, et al. Improving client engagement and retention in treatment: The Los Angeles County experience. J Subst Abuse Treat. 2010; 39(1): 78-86. doi:10.1016/j.jsat.2010.03.015.

  130. Guy R, Hocking J, Wand H, Stott S, Ali H, Kaldor J. How effective are short message service reminders at increasing clinic attendance? A meta-analysis and systematic review. Health Serv Res. 2012; 47(2): 614-632. doi:10.1111/j.1475-6773.2011.01342.x.

  131. Gurol-Urganci I, De Jongh T, Atun R, Car J. Mobile phone messaging reminders for attendance at healthcare appointments. Cochrane Database Syst Rev. 2012; (7): CD007458. doi:10.1002/14651858.CD007458.pub2.

  132. Hasvold PE, Wootton R. Use of telephone and SMS reminders to improve attendance at hospital appointments: a systematic review. J Telemed Telecare. 2011; 17(7): 358-364. doi:10.1258/jtt.2011.110707.

  133. Spohr SA, Taxman FS, Walters ST. The relationship between electronic goal reminders and subsequent drug use and treatment initiation in a criminal justice setting. Addict Behav. 2015; 51: 51-56. doi:10.1016/j.addbeh.2015.07.005.

  134. Bradley KA, Kivlahan DR. Bringing patient-centered care to patients with alcohol use disorders. JAMA. 2014; 311(18): 1861-1862. doi:10.1001/jama.2014.3629.

  135. Moses K, Klebonis J. Designing Medicaid health homes for individuals with opioid dependency: Considerations for states. Health Home Information Resource Center. Baltimore, MD: CMS; 2015. Accessed September 21, 2017.

  136. Epstein RM, Fiscella K, Lesser CS, Stange KC. Why the nation needs a policy push on patient-centered health care. Health Aff (Millwood). 2010; 29(8): 1489-1495. doi:10.1377/hlthaff.2009.0888.

  137. Légaré F, Witteman HO. Shared decision making: Examining key elements and barriers to adoption into routine clinical practice.Health Aff (Millwood). 2013; 32(2): 276-284. doi:10.1377/hlthaff.2012.1078.

  138. Barry MJ, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered care. N Engl J Med. 2012; 366(9): 780-781. doi:10.1056/NEJMp1109283.

  139. Miles J, Mericle AA, Way F, Cacciola J. Patient-centered care coordination: A qualitative study of the lived experience of residents in Philadelphia recovery homes. Addict Sci Clin Pract. 2015; 10(Suppl 1): A39. doi:10.1186/1940-0640-10-S1-A39.

  140. Xing J, Goehring C, Mancuso D. Care coordination program for Washington state Medicaid enrollees reduced inpatient hospital costs. Health Aff (Millwood). 2015; 34(4): 653-661. doi:10.1377/hlthaff.2014.0655.

  141. Brown RS, Peikes D, Peterson G, Schore J, Razafindrakoto CM. Six features of Medicare coordinated care demonstration programs that cut hospital admissions of high-risk patients. Health Aff (Millwood). 2012; 31(6): 1156-1166. doi:10.1377/hlthaff.2012.0393.

  142. Healthcare Fraud Prevention Partnership. Healthcare Payer Strategies to Reduce the Harms of Opioids. White Paper. Baltimore, MD: CMS; 2017.

  143. Oregon Health Authority (OHA). Behavioral Health Collaborative Report. Salem, OR: OHA; 2017. Accessed September 21, 2017.

  144. California Health Care Foundation. Case Studies: Three California Health Plans Take Action Against Opioid Overuse. Oakland, CA: California Health Care Foundation; 2017.

  145. Centers for Medicare & Medicaid Services (CMS). License Agreements. CMS website; 2017. Accessed September 21, 2017.

  146. Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality. 2013-2014 National Survey on Drug Use and Health: Model-Based Prevalence Estimates (50 States and the District of Columbia). BHSIS Series S-73, HHS Publication No. (SMA) 14-489. Rockville, MD: SAMHSA; 2014.

  147. Centers for Disease Control and Prevention (CDC). Opioid Painkiller Prescribing Infographic. CDC website. Atlanta, GA: CDC. Updated July 1, 2014. Accessed April 6, 2016.

  148. Substance Abuse and Mental Health Services Administration (SAMHSA). National Survey of Substance Abuse Treatment Services (N-SSATS): 2013. Data on Substance Abuse Treatment Facilities. BHSIS Series S-73, HHS Publication No. (SMA) 14-4890. Rockville, MD: SAMHSA; 2014.

  149. Substance Abuse and Mental Health Services Administration (SAMHSA). Buprenorphine Treatment Physician Locator. SAMHSA website. Accessed April 6, 2016.

  150. U.S. Census Bureau. 2014 Population Estimates, Data. U.S. Census Bureau website. Accessed April 6, 2016.

  151. U.S. Census Bureau. QuickFacts, United States (2014). U.S. Census Bureau website. . Accessed April 6, 2016.

  152. U.S. Census Bureau. Poverty, Poverty Thresholds (2014). U.S. Census Bureau website. Accessed April 6, 2016.

  153. U.S. Census Bureau. Health Insurance Data (2014). U.S. Census Bureau website. Accessed April 6, 2016.

  154. National Alliance for Model State Drug Laws (NAMSDL). 2015 Annual Review of Prescription Monitoring Programs. Manchester, IA: NAMSDL; 2015.

  155. Substance Abuse and Mental Health Services Administration (SAMHSA). Funding and Characteristics of Single State Agencies for Substance Abuse Services and State Mental Health Agencies, 2013. HHS Publication No. SMA-15-4926. Rockville, MD: SAMHSA; 2015.

  156. Harris KM, Edlund MJ. Use of mental health care and substance abuse treatment among adults with co-occurring disorders. Psychiatr Serv. 2005; 56(8): 954-959. doi:10.1176/

  157. Roberts AW, Farley JF, Holmes GM, et al. Controlled substance lock-in programs: Examining an unintended consequence of a prescription drug abuse policy. Health Aff (Millwood). 2016; 35(10): 1884-1892. doi:10.1377/hlthaff.2016.0355.